Macquarie Group Ltd. boosted its holdings in Epizyme, Inc. (NASDAQ:EPZM) by 105.5% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 41,100 shares of the biopharmaceutical company’s stock after buying an additional 21,100 shares during the period. Macquarie Group Ltd. owned 0.06% of Epizyme worth $783,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of EPZM. Legal & General Group Plc boosted its stake in Epizyme by 8.9% in the 1st quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 795 shares during the last quarter. BB&T Securities LLC acquired a new position in shares of Epizyme in the 2nd quarter valued at about $181,000. Trexquant Investment LP acquired a new position in shares of Epizyme in the 2nd quarter valued at about $184,000. SG Americas Securities LLC lifted its stake in shares of Epizyme by 83.3% in the 2nd quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock valued at $202,000 after purchasing an additional 6,072 shares in the last quarter. Finally, Tudor Investment Corp ET AL acquired a new position in shares of Epizyme in the 2nd quarter valued at about $215,000. 85.28% of the stock is currently owned by hedge funds and other institutional investors.

EPZM has been the topic of several research analyst reports. Cann reaffirmed a “buy” rating and issued a $26.00 price objective on shares of Epizyme in a research note on Tuesday. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Epizyme in a research note on Thursday, November 2nd. Zacks Investment Research raised Epizyme from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a research note on Monday, October 16th. Jefferies Group initiated coverage on Epizyme in a research note on Wednesday, September 20th. They issued a “buy” rating and a $23.00 price objective on the stock. Finally, Oppenheimer reaffirmed a “buy” rating and issued a $26.00 price objective on shares of Epizyme in a research note on Tuesday, September 19th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $22.67.

Shares of Epizyme, Inc. (NASDAQ:EPZM) opened at $12.85 on Tuesday. Epizyme, Inc. has a twelve month low of $9.30 and a twelve month high of $20.45.

Epizyme (NASDAQ:EPZM) last announced its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.02. sell-side analysts expect that Epizyme, Inc. will post -2.23 EPS for the current year.

In related news, Director David M. Mott bought 200,000 shares of the company’s stock in a transaction that occurred on Monday, September 18th. The shares were acquired at an average cost of $15.25 per share, for a total transaction of $3,050,000.00. Following the acquisition, the director now owns 6,000 shares in the company, valued at approximately $91,500. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Peter Tai-Ching Ho sold 15,000 shares of the firm’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $16.81, for a total value of $252,150.00. Following the sale, the insider now owns 23,123 shares in the company, valued at $388,697.63. The disclosure for this sale can be found here. Company insiders own 25.20% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was first published by Daily Political and is owned by of Daily Political. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/12/12/epizyme-inc-epzm-shares-bought-by-macquarie-group-ltd.html.

About Epizyme

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).

Institutional Ownership by Quarter for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.